Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott Laboratories' diabetes care division has taken legal action against DexCom, alleging that the San Diego-based firm's glucose monitoring system infringes on its patents.
Subscribe to our email newsletter
DexCom has said that it believes the complaint to be without merit, and it intends to “vigorously contest the action”.
In a statement DexCom remarked. “DexCom…believes the complaint filed by Abbott is largely an attempt by a much larger and established company to intimidate and distract DexCom, a much smaller company, from commercializing its STS continuous glucose monitoring system, a new and potentially important technology for people with diabetes.”
Abbott announced on Monday, August 15th, that it had received FDA clearance for its glucose monitoring system, which will be marketed under the name FreeStyle Connect. The device measures glucose levels using a very small blood sample size (0.3 micro liters) and produces results within an average of 15 seconds.